These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21586891)

  • 21. An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer.
    Salzberg M; Rochlitz C; Morant R; Thalmann G; Pedrazzini A; Roggero E; Schönenberger A; Knuth A; Borner M
    Onkologie; 2007 Jul; 30(7):355-60. PubMed ID: 17596743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
    Ferrero JM; Chamorey E; Oudard S; Dides S; Lesbats G; Cavaglione G; Nouyrigat P; Foa C; Kaphan R
    Cancer; 2006 Aug; 107(4):738-45. PubMed ID: 16826591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).
    Kattan JG; Farhat FS; Chahine GY; Nasr FL; Moukadem WT; Younes FC; Yazbeck NJ; Ghosn MG;
    Invest New Drugs; 2008 Feb; 26(1):75-9. PubMed ID: 17846704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of UFT on treatment of urological cancer--effect of UFT on treatment of invasive bladder cancer and advanced prostate cancer. Ibaraki Urological Cancer Chemotherapy Study Group].
    Uchida K; Takeshima H; Kikuchi K; Shimazui T; Miyanaga N; Kawai K; Akaza H; Tsuchiya A; Noguchi R; Hattori K; Manabe F; Matsuki K; Suzuki R; Ishikawa S; Kondo F; Kobayashi T; Koiso K
    Gan To Kagaku Ryoho; 1998 Jul; 25(8):1179-87. PubMed ID: 9679581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.
    Nakabayashi M; Sartor O; Jacobus S; Regan MM; McKearn D; Ross RW; Kantoff PW; Taplin ME; Oh WK
    BJU Int; 2008 Feb; 101(3):308-12. PubMed ID: 18184327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
    Machiels JP; Mazzeo F; Clausse M; Filleul B; Marcelis L; Honhon B; D'Hondt L; Dopchie C; Verschaeve V; Duck L; Verhoeven D; Jousten P; Bonny MA; Moxhon AM; Tombal B; Kerger J
    J Clin Oncol; 2008 Nov; 26(32):5261-8. PubMed ID: 18794543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
    Oh WK; Hagmann E; Manola J; George DJ; Gilligan TD; Jacobson JO; Smith MR; Kaufman DS; Kantoff PW
    Clin Cancer Res; 2005 Jan; 11(1):284-9. PubMed ID: 15671557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer.
    Safarinejad MR
    Urol Oncol; 2005; 23(2):93-101. PubMed ID: 15869993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Docetaxel-based chemotherapy for hormone-refractory prostate cancer in Japanese patients : experience in a single institute].
    Kinebuchi Y; Wajiki M; Suzuki A; Tsuruta T; Kawaguchi K
    Hinyokika Kiyo; 2011 Sep; 57(9):481-6. PubMed ID: 22075607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis.
    Hahn NM; Marsh S; Fisher W; Langdon R; Zon R; Browning M; Johnson CS; Scott-Horton TJ; Li L; McLeod HL; Sweeney CJ
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6094-9. PubMed ID: 17062685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
    Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
    Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hormonal chemotherapy for hormone-refractory prostate cancer].
    Nishimura K; Nakai Y; Shimizu K; Tokizane T; Arai Y; Inoue H; Takaha N; Nonomura N; Okuyama A; Kamoi K; Ukimura O; Miki T; Koide T; Ichikawa Y; Nishimura K; Sugao H; Yamaguchi S; Takatera H; Uchida K; Miura H
    Hinyokika Kiyo; 2002 Nov; 48(11):713-8. PubMed ID: 12512147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Docetaxel in combination with prednisolone for hormone refractory prostate cancer.
    Ide H; Kikuchi E; Kono H; Nagata H; Miyajima A; Nakagawa K; Ohigashi T; Nakashima J; Oya M
    Jpn J Clin Oncol; 2010 Jan; 40(1):79-84. PubMed ID: 19837689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Low-dose docetaxel, estramustine and dexamethasone combination chemotherapy for hormone-refractory prostate cancer].
    Kobayashi K; Yokonishi T; Ito Y; Matsumoto T; Umemoto S; Osaka K; Nakamura M; Onuki T; Komiya A; Ohgo Y; Sakai N; Noguchi S; Kishi H; Yokomizo Y; Kawai M; Okajima K; Tajiri T; Fujikawa A; Ohta J; Yumura Y; Moriyama M
    Hinyokika Kiyo; 2010 Apr; 56(4):203-7. PubMed ID: 20448443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer.
    Ferrero JM; Foa C; Thezenas S; Ronchin P; Peyrade F; Valenza B; Lesbats G; Garnier G; Boublil JL; Tchiknavorian X; Chevallier D; Amiel J
    Oncology; 2004; 66(4):281-7. PubMed ID: 15218295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy.
    Nelius T; Klatte T; de Riese W; Haynes A; Filleur S
    Med Oncol; 2010 Jun; 27(2):363-7. PubMed ID: 19365737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
    Berry W; Eisenberger M
    Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel.
    Petrioli R; Pascucci A; Francini E; Marsili S; Sciandivasci A; De Rubertis G; Barbanti G; Manganelli A; Salvestrini F; Francini G
    BJU Int; 2007 Oct; 100(4):775-9. PubMed ID: 17535276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endocrine plus uracil/tegafur therapy for prostate cancer.
    Ono Y; Ohshima S; Takahashi Y; Kuriyama M; Kawada Y; Shimizu H
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):120-4. PubMed ID: 10442379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.